scispace - formally typeset
Open AccessJournal ArticleDOI

The proximal origin of SARS-CoV-2.

Reads0
Chats0
TLDR
It is shown that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus, and scenarios by which they could have arisen are discussed.
Abstract
SARS-CoV-2 is the seventh coronavirus known to infect humans; SARSCoV, MERS-CoV and SARS-CoV-2 can cause severe disease, whereas HKU1, NL63, OC43 and 229E are associated with mild symptoms6. Here we review what can be deduced about the origin of SARS-CoV-2 from comparative analysis of genomic data. We offer a perspective on the notable features of the SARS-CoV-2 genome and discuss scenarios by which they could have arisen. Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Perspectives on the development of neutralizing antibodies against SARS-CoV-2.

TL;DR: In this paper, a broad-neutralizing antibody against SARS-CoV-2 and SARS CoV is proposed for treating not only COVID-19 but also future SARSrelated CoV infections.
Journal ArticleDOI

Validation and Psychometric Properties of the Portuguese Version of the Coronavirus Anxiety Scale (CAS) and Fear of COVID-19 Scale (FCV-19S) and Associations with Travel, Tourism and Hospitality.

TL;DR: In this article, the Coronavirus Anxiety Scale (CAS) and Fear of COVID-19 Scale (FCV-19S) were validated for the Portuguese population and correlations with issues related to travel, tourism and hospitality were established.
Journal ArticleDOI

SARS-CoV-2 genomic surveillance identifies naturally occurring truncation of ORF7a that limits immune suppression.

TL;DR: Using global phylogenomics, this article showed that mutations frequently occur in the C-terminal end of ORF7a, which negates anti-immune activities of the protein, which results in elevated type I interferon response to the viral infection.
Journal ArticleDOI

Taming the Autophagy as a Strategy for Treating COVID-19.

TL;DR: There is conclusive evidence about the substantial contribution of two concomitant factors to the development of severe COVID-19: a delayed or absent type I and III interferon (IFN-I and IFN-III) response together with robust cytokine and chemokine production.
Journal ArticleDOI

Analysis of the Impact of COVID-19 on the Food and Beverages Manufacturing Sector

TL;DR: The Food and Beverages Manufacturing sector in South Africa (SA) and globally is an expeditious respondent to the COVID-19 challenge as discussed by the authors, and the food value chain is subjected to significant COVID19 risks, but the resolution of this unprecedented challenge does not seem to be in the short-term horizon but rather something the globe has to live with.
References
More filters
Journal ArticleDOI

A pneumonia outbreak associated with a new coronavirus of probable bat origin

TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI

A new coronavirus associated with human respiratory disease in China.

TL;DR: Phylogenetic and metagenomic analyses of the complete viral genome of a new coronavirus from the family Coronaviridae reveal that the virus is closely related to a group of SARS-like coronaviruses found in bats in China.
Journal ArticleDOI

An interactive web-based dashboard to track COVID-19 in real time.

TL;DR: The outbreak of the 2019 novel coronavirus disease (COVID-19) has induced a considerable degree of fear, emotional stress and anxiety among individuals around the world.
Journal ArticleDOI

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Related Papers (5)